INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 421m ago
HOUSE PTR21m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Dreyer Scott sold COLL

EVP & Chief Commercial Officer · COLLEGIUM PHARMACEUTICAL, INC · Common Stock

Side
SELL
Value
$315K
Shares
6,475
Price
$48.66
Executed
Dec 8, 2025
Disclosed
Dec 10, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Dec 8 executedDec 10, 2025 disclosed

COLL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+11 / 25

    $315K reported value · 5.9% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · COLL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GM
    Glancy Donovan MichaelDirector
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    17.5K sh
    		May 14, 2026May 18, 2026
    traded May 14, 2026
    		+4dSEC FORM 4

    Evidence

    25
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$316K
    8,840 sh
    		Mar 17, 2026Apr 3, 2026
    traded Mar 17, 2026
    		+17dSEC FORM 4

    Evidence

    11
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$488K
    14.0K sh
    		Mar 18, 2026Mar 20, 2026
    traded Mar 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$228K
    6,224 sh
    		Mar 9, 2026Mar 11, 2026
    traded Mar 9, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    32.7K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    17
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    22.2K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    13
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    9,005 sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    12
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$130K
    2,781 sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    26.4K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    15
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$555K
    11.9K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    22
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$1.25M
    26.7K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    0
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Option exercise · 10b5-1 plan
    		M—
    17.6K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    20
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$533K
    11.1K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Option exercise · 10b5-1 plan
    		M$280K
    17.6K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    33
    BJ
    Balice-Gordon Rita J.Director
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale
    		SELL$172K
    3,650 sh
    		Dec 5, 2025Dec 9, 2025
    traded Dec 5, 2025
    		+4dSEC FORM 4

    Evidence

    19
    KV
    Karnani VikramDirector, President and CEO
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$425K
    8,983 sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    18
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$1.02M
    25.1K sh
    		Nov 6, 2025Nov 7, 2025
    traded Nov 6, 2025
    		+1dSEC FORM 4

    Evidence

    8
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$201K
    4,858 sh
    		Nov 6, 2025Nov 7, 2025
    traded Nov 6, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001746251-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 8, 2025
    Published
    Dec 10, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Dreyer Scott
    Role
    EVP & Chief Commercial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    COLLEGIUM PHARMACEUTICAL, INC
    Ticker
    COLL
    Shares
    6,475
    Price per share
    $48.66
    Value
    $315,085
    Execution date (reported)
    Dec 8, 2025
    Owned after transaction
    103.6K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 6,475
    • Price: $48.6617

    = $315,085

    What this establishes

    Dreyer Scott filed this Form 4 reporting a open-market sale of COLL on Dec 8, 2025. It became public on Dec 10, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP & Chief Commercial Officer
    Dreyer Scottcik:0001746251
    Issuer
    COLLEGIUM PHARMACEUTICAL, INCcik:0001267565

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.